Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTMEGFR V2 and NGS Technologies

被引：0
|
作者：
Jessica Garcia
Arnaud Gauthier
Gaëlle Lescuyer
David Barthelemy
Florence Geiguer
Julie Balandier
Daniel L. Edelstein
Frederick S. Jones
Frank Holtrup
Mickael Duruisseau
Emmanuel Grolleau
Claire Rodriguez-Lafrasse
Patrick Merle
Sébastien Couraud
Léa Payen
机构：
[1] Hospices Civils de Lyon,Laboratoire de Biochimie et Biologie Moléculaire, Groupe Hospitalier Sud
[2] Hospices Civils de Lyon Cancer Institute,Service de Pneumologie, Groupement Hospitalier Est
[3] CIRculating CANcer (CIRCAN) Program,Service de Pneumologie
[4] Life Sciences Medical Affairs and Research and Development Sysmex Inostics,Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique, Groupement Hospitalier Sud
[5] GmBH,EMR 3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon
[6] Hospices Civils de Lyon,Sud
[7] Centre Hospitalier Gabriel Montpied,undefined
[8] Institut de Cancérologie des Hospices Civils de Lyon,undefined
[9] Université de Lyon,undefined
[10] Hospices Civils de Lyon,undefined
[11] Centre Hospitalier Lyon Sud,undefined
来源：
Molecular Diagnosis & Therapy | 2021年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：239 / 250
页数：11
相关论文
共 28 条
  • [1] Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTMEGFR V2 and NGS Technologies
    Garcia, Jessica
    Gauthier, Arnaud
    Lescuyer, Gaelle
    Barthelemy, David
    Geiguer, Florence
    Balandier, Julie
    Edelstein, Daniel L.
    Jones, Frederick S.
    Holtrup, Frank
    Duruisseau, Mickael
    Grolleau, Emmanuel
    Rodriguez-Lafrasse, Claire
    Merle, Patrick
    Couraud, Sebastien
    Payen, Lea
    MOLECULAR DIAGNOSIS & THERAPY, 2021, 25 (02) : 239 - 250
  • [2] Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays
    Barthelemy, David
    Lescuyer, Gaelle
    Geiguer, Florence
    Grolleau, Emmanuel
    Gauthier, Arnaud
    Balandier, Julie
    Raffin, Margaux
    Bardel, Claire
    Bouyssounouse, Bruno
    Rodriguez-Lafrasse, Claire
    Couraud, Sebastien
    Wozny, Anne-Sophie
    Payen, Lea
    CANCERS, 2023, 15 (05)
  • [3] Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using OncoBEAMTM EGFR V2, targeted next-generation sequencing Plasma-SeqSenseiTM Solid Cancer IVD Kit and custom-validated NGS assay
    Barthelemy, David
    Grolleau, Emmanuel
    Lescuyer, Gaelle
    Geiguer, Florence
    Gauthier, Arnaud
    Balandier, Julie
    Raffin, Margaux
    Bardel, Claire
    Bouyssounouse, Bruno
    Rodriguez-Lafrasse, Claire
    Couraud, Sebastien
    Wozny, Anne-Sophie
    Payen-Gay, Lea
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)
    Kushnir, M.
    Winter, H.
    Murias, C.
    Bains, P.
    Abbosh, C. Z.
    Papadatos-Pastos, D.
    Newsome-Davis, T.
    Ahmed, T.
    Swanton, C.
    Forster, M. D.
    Moore, D.
    Bennett, P.
    Faull, I.
    Lanman, R. B.
    Arkenau, H-T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Predictive factors for detectability of genomic alterations from circulating cell-free DNA in patients with advanced non-small cell lung cancer
    Kimura, H.
    Koba, H.
    Kasahara, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGS
    Peled, Nir
    Belilovski-Rozenblum, Anna
    Soussan-Gutman, Lior
    Lee, Christine
    Talasaz, AmirAli
    Lanman, Richard B.
    CANCER RESEARCH, 2016, 76
  • [7] Cell-free circulating tumour DNA (ctDNA) in the management of patients (pts) with non-biopsiable (Bx) advanced non-small cell lung cancer (NSCLC).
    Kushnir, MArina
    Murias, Carmen
    Winter, Helen
    Bain, Param
    Abbosh, Christopher
    Papadatos, Dionysis
    Newsom-Davis, Thomas
    Ahmad, Tanya
    Swanton, Charles
    Forster, Martin David
    Moore, David Allan
    Bennett, Philip
    Faull, Iris
    Lanman, Richard B.
    Arkenau, Hendrik-Tobias
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Del Re, Marzia
    Vasile, Enrico
    Falcone, Alfredo
    Danesi, Romano
    Petrini, Iacopo
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (04) : 453 - 468
  • [9] Association of circulating tumor DNA clearance during treatment with improved progression-free survival in advanced non-small cell lung cancer patients.
    Lu, Shun
    Song, Yong
    Xie, Zhanhong
    Li, Min
    Zhu, Zhengfei
    Liu, Li
    Dong, Xiaorong
    Chen, Yuan
    Zheng, Di
    Zhao, Weixin
    Chang, Jian Hua
    Jin, Meiling
    Hu, Jie
    Tong, Gangling
    Rao, Chuangzhou
    Xu, Haiyan
    Zhang, Lu
    Mao, Xinru
    Han-Zhang, Han
    Liu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
    Wei-Wei Peng
    Ying Liu
    Huan-Huan Sha
    Shao-Di Wen
    Ying Fang
    Guo-Ren Zhou
    BMC Pulmonary Medicine, 23
123